AQR Capital Management LLC lowered its position in shares of PetIQ, Inc. (NASDAQ:PETQ – Free Report) by 17.0% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 266,508 shares of the company’s stock after selling 54,650 shares during the quarter. AQR Capital Management LLC owned approximately 0.90% of PetIQ worth $5,879,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in PETQ. Campbell & CO Investment Adviser LLC increased its holdings in shares of PetIQ by 24.3% during the fourth quarter. Campbell & CO Investment Adviser LLC now owns 41,377 shares of the company’s stock worth $817,000 after buying an additional 8,083 shares in the last quarter. Nomura Holdings Inc. increased its holdings in PetIQ by 7.1% during the 4th quarter. Nomura Holdings Inc. now owns 423,496 shares of the company’s stock valued at $8,364,000 after purchasing an additional 28,231 shares in the last quarter. Goldman Sachs Group Inc. raised its position in PetIQ by 11.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,036,292 shares of the company’s stock valued at $20,467,000 after purchasing an additional 108,870 shares during the last quarter. Wellington Management Group LLP acquired a new position in PetIQ in the fourth quarter worth $1,410,000. Finally, Los Angeles Capital Management LLC grew its holdings in shares of PetIQ by 196.6% during the first quarter. Los Angeles Capital Management LLC now owns 129,632 shares of the company’s stock worth $2,370,000 after purchasing an additional 85,920 shares during the last quarter. 94.99% of the stock is owned by institutional investors.
PetIQ Price Performance
Shares of PETQ stock opened at $30.87 on Friday. The firm has a market cap of $922.70 million, a price-to-earnings ratio of 140.32 and a beta of 1.73. PetIQ, Inc. has a 12 month low of $15.09 and a 12 month high of $30.89. The company has a quick ratio of 1.68, a current ratio of 2.58 and a debt-to-equity ratio of 1.68. The stock has a 50-day moving average price of $29.12 and a 200 day moving average price of $22.93.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on PETQ. Truist Financial downgraded shares of PetIQ from a “buy” rating to a “hold” rating and upped their price target for the stock from $30.00 to $31.00 in a research report on Thursday, August 8th. William Blair lowered shares of PetIQ from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, PetIQ currently has an average rating of “Moderate Buy” and a consensus target price of $29.67.
Read Our Latest Research Report on PetIQ
About PetIQ
PetIQ, Inc operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats.
Read More
- Five stocks we like better than PetIQ
- What Does Downgrade Mean in Investing?
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- How to Use Stock Screeners to Find Stocks
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Want to see what other hedge funds are holding PETQ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PetIQ, Inc. (NASDAQ:PETQ – Free Report).
Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.